• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Bavarian Nordic

182.60 DKK

+1.78 %

Less than 1K followers

BAVA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.78 %
-2.87 %
-1.30 %
-4.32 %
-3.92 %
+1.73 %
-5.80 %
-34.13 %
+28.02 %

Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Read more
Market cap
14.47B DKK
Turnover
22.43M DKK
Revenue
6.24B
EBIT %
28.89 %
P/E
10.37
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21/8
2026

Interim report Q2'26

13/11
2026

Interim report Q3'26

Regulatory press release6/2/2026, 6:11 AM

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

Bavarian Nordic
Regulatory press release5/13/2026, 7:01 PM

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic
Regulatory press release5/13/2026, 5:35 AM

Bavarian Nordic Announces Interim Results for the First Three Months of 2026

Bavarian Nordic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/11/2026, 4:30 PM

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines

Bavarian Nordic
Regulatory press release5/11/2026, 7:12 AM

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic
Regulatory press release5/4/2026, 8:45 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release4/27/2026, 6:57 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release4/21/2026, 6:39 PM

Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S

Bavarian Nordic
Regulatory press release4/20/2026, 11:27 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Press release4/16/2026, 5:30 AM

Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine

Bavarian Nordic
Regulatory press release4/13/2026, 6:45 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release4/7/2026, 8:47 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release3/30/2026, 8:13 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Press release3/27/2026, 7:00 AM

Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years

Bavarian Nordic
Regulatory press release3/24/2026, 11:30 AM

Bavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic
Regulatory press release3/23/2026, 8:11 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release3/16/2026, 9:53 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release3/12/2026, 7:30 PM

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic
Regulatory press release3/12/2026, 6:51 AM

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

Bavarian Nordic
Regulatory press release3/12/2026, 6:39 AM

Bavarian Nordic Publishes Annual Report 2025

Bavarian Nordic